Barber P A, Hill M D, Demchuk A M, Buchan A M
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
Can J Neurol Sci. 2000 Nov;27(4):283-7. doi: 10.1017/s0317167100001001.
Alteplase for acute ischemic stroke may be the first stroke intervention to have a significant public health impact. In February 1999, this therapy was conditionally licensed in Canada for acute ischemic stroke within three hours of symptom onset. However, considerable controversy exists regarding its safety, its wider applicability outside clinical trials, and its ultimate availability. In this article we review the thrombolytic literature, attempt to answer many of the concerns, provide new guidelines for its use, and cite the need for more information about whom we should and should not be treating with this therapy.
阿替普酶用于急性缺血性卒中可能是首个对公共卫生有重大影响的卒中干预措施。1999年2月，该疗法在加拿大获得有条件许可，用于症状发作三小时内的急性缺血性卒中。然而，关于其安全性、在临床试验之外的更广泛适用性以及最终的可及性，存在相当大的争议。在本文中，我们回顾了溶栓文献，试图回答许多相关问题，提供使用该疗法的新指南，并指出需要更多关于哪些患者应该和不应该接受该疗法治疗的信息。
